Invesco Perpetual

Pharma stocks could be "dramatically re-rated" in the next three to four years, said PSigma's Bill Mott, as analysts realise it is one of the few sectors that can deliver shareholder returns in the face of economic uncertainty.

Income stars such as Neil Woodford and Bill Mott are set for boosts to their portfolios as AstraZeneca jumped over 3% this morning following the approval of a drug the pharma giant pinned $2bn of future sales.

Invesco Perpetual's Paul Causer and Paul Read have allocated nearly a quarter of their £398m Tactical Bond fund to Spanish and Italian bonds in the view the countries are "too big to fail".

Invesco Perpetual's Andrew Shard, who heads up the group's £351m US Equity fund, has left the firm.

The Financial Services Authority has warned investors an unauthorised firm masquerading as Invesco Perpetual is attempting to sell fake funds.

Oriel Securities has highlighted the top equity based investment trusts yielding more than the FTSE 100, FTSE 250 and Small Cap.

Neil Woodford's Invesco Perpetual income funds have leapt to the top of the performance tables after two years of underperformance as the manager's value calls finally start to pay off.

Ex-iShares and Gartmore sales director Julian Hince has joined M&G as technical development director.

Neil Woodford is poised to increase the limit on overseas investments in his £940m Edinburgh investment trust to 20%, as the manager continues to find better income opportunities outside of the UK.

Nick Mustoe, chief investment officer at Invesco Perpetual, says attention has now shifted from global tensions to optimism about the US economic recovery.